SCHEMBL19360919

SCHEMBL19360919

C[C@H](CCCN)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)CC4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.89

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 6/20 0.89
▸ GPBAR1 Q8TDU6 12/20 0.82
▸ MEN1 O00255 2/20 0.72
▸ KMT2A Q03164 2/20 0.72
▸ ABCB11 O95342 2/20 0.72
▸ SLC10A2 Q12908 2/20 0.72
▸ LMNA P02545 1/20 0.72
▸ CYP2C19 P33261 1/20 0.72
▸ CHRM2 P08172 1/20 0.72
▸ ADRA2A P08913 1/20 0.72
▸ ADRA1A P35348 1/20 0.72
▸ TDP1 Q9NUW8 1/20 0.72
▸ ENPP2 Q13822 1/20 0.72
▸ SLC10A1 Q14973 1/20 0.72
▸ CISD1 Q9NZ45 1/20 0.72
▸ CYP3A4 P08684 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23704708 0.94 NR1H4 (1.00) NR1H4GPBAR1MEN1KMT2AABCB11
SCHEMBL26753814 0.94 NR1H4 (1.00) NR1H4GPBAR1MEN1KMT2AABCB11
SCHEMBL26424172 0.94 NR1H4 (1.00) NR1H4GPBAR1MEN1KMT2AABCB11
SCHEMBL23704706 0.94 NR1H4 (1.00) NR1H4GPBAR1MEN1KMT2AABCB11
SCHEMBL26426247 0.94 NR1H4 (1.00) NR1H4GPBAR1MEN1KMT2AABCB11
SCHEMBL19360888 0.92 GPBAR1 (0.87) NR1H4GPBAR1MEN1KMT2AABCB11
SCHEMBL25943252 0.92 GPBAR1 (0.87) NR1H4GPBAR1MEN1KMT2AABCB11
SCHEMBL19360871 0.92 GPBAR1 (0.87) NR1H4GPBAR1MEN1KMT2AABCB11
SCHEMBL19360872 0.92 GPBAR1 (0.87) NR1H4GPBAR1MEN1KMT2AABCB11
SCHEMBL25943247 0.92 GPBAR1 (0.87) NR1H4GPBAR1MEN1KMT2AABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701369-B2 Polymeric bile acid derivatives inhibit Hepatitis B and D virus and NTCP transport HUAHUI HEALTH LTD. (CN) 2023-07-18 — — US disclosed
US-11701369-B2 Polymeric bile acid derivatives inhibit Hepatitis B and D virus and NTCP transport HUAHUI HEALTH LTD. (CN) 2023-07-18 — — US disclosed
US-20170266206-A1 POLYMERIC BILE ACID DERIVATIVES INHIBIT HEPATITIS B AND D VIRUS AND NTCP TRANSPORT HUAHUI HEALTH LTD. (CN) 2017-09-21 — — US disclosed
US-20170266206-A1 POLYMERIC BILE ACID DERIVATIVES INHIBIT HEPATITIS B AND D VIRUS AND NTCP TRANSPORT HUAHUI HEALTH LTD. (CN) 2017-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701369-B2 Polymeric bile acid derivatives inhibit Hepatitis B and D virus and NTCP transport SLC10A1, SLC10A2, ABCB11 NR1H4 6/4885GPBAR1 17/4885MEN1 4307/4885
US-20170266206-A1 POLYMERIC BILE ACID DERIVATIVES INHIBIT HEPATITIS B AND D VIRUS AND NTCP TRANSPORT SLC10A1, SLC10A2, ABCB11 NR1H4 6/4885GPBAR1 17/4885MEN1 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback